W hereas 1-4% of TN cases are associated with MS plaques or lacunar infarctions within the brainstem trigeminal system or with cerebellopontine angle mass lesions, 5, 16, 24 the best empiric evidence and scientific hypotheses to date suggest that most cases are caused by focal compression of the root entry zone of the trigeminal nerve root. 3, 14, 18, 20, 22, 23, 51, 56 Current surgical options in patients who have inadequate or only transient relief with medical therapy include MVD 3, 4, 9, 12, 29, 30, 44, 55 or one of several palliative destructive procedures directed at the trigeminal nerve root or ganglion. Stereotactic GKS has recently joined percutaneous retrogasserian RFL, 10, 27, 48, 57, 59 PRGR, 21, 25, 47, 61 and PBC 11, 32 as the newest method for performing a trigeminal rhizotomy. [6] [7] [8] 31, 41, 45, 49, 50, 52, 53, 62 The duration of clinical follow-ups in recent reports on GKS has been relatively short. Nevertheless, the initial response of both patients and referring physicians to this newest treatment has been very enthusiastic.
tended clinical follow-ups have now been published. 3, 4, 9, 12, 29, 30, 44, 55 Authors of several published articles have presented and critically discussed the relative roles of MVD versus palliative percutaneous rhizotomy in the surgical management of TN. 1, 13, 39, 59 There has been one retrospective comparison of MVD versus GKS, both procedures performed by the same surgeon. 49 Moreover, there has been only one prospective cohort study of MVD versus GKS in which one surgeon performed both procedures, and this study did not reach statistical significance during the short follow-up period. 7 Our aim in this prospective clinical cohort study was to compare GKS and MVD performed by one surgeon with significant experience in both procedures.
Methods
To be considered "typical," TN must have caused intermittent paroxysmal attacks of shocklike, lancinating pain in the trigeminal distribution together with a history of tactile triggering. The attacks could occur in tetanic clusters that lasted for some time, but the actual individual shocks could last no longer than seconds to minutes. A history of minor atypical features was permitted only if the typical features represented at least 80% of the patient's overall symptoms. Features considered "atypical" included mild background dull, constant, or burning pain, associated headache, or failure to respond initially to treatment with AEDs. Patients with MS or predominantly dull, burning, and/or constant facial pain were excluded. Patients with TN due to compression from a dolichoectatic vertebrobasilar system were excluded. 35 In a 4.75-year period between March 1999 and December 2003, 133 patients with typical TN were referred to the senior author (M.E.L.) for evaluation. Thirty-three (25%) were treated with additional medical therapy. Twenty (15%) had undergone nerve root or ganglion surgery elsewhere, but the disease recurred. The remaining 80 patients (60%) who were underwent their first surgical procedure with us constitute the subject of this report. Patients were not randomized. Although all procedures were discussed with all patients, treatments were selected on the following basis. For those who were young and healthy we recommended MVD and proceeded to GKS only if patient choice overrode physician recommendation (36-45%). For those who were older, had significant medical problems, or refused the recommended MVD, GKS was performed (44-55%). The institutional review board at the University of Arkansas for Medical Science reviewed this study.
Treatment Protocols
Microvascular decompression was performed using shredded Teflon felt for the decompressive material, and intraoperative auditory brainstem evoked potential monitoring was used in all cases. The general technique has been described elsewhere. 35, 40 Intraoperative microsurgical observations were recorded.
Stereotactic GKS was performed using a Leksell Gamma Unit (model B, Elekta) with a 4-mm collimator helmet and a collimator output factor of 0.87. The general technique of GKS has been described elsewhere. 31 A prescription dose of 80 Gy was administered in 42 patients and 90 Gy in 2 patients. In 26 patients (59.1%) a beam-blocking pattern of 50-100 201 sources was used to keep the 20% isodose line at the surface of the brainstem. The target point was the trigeminal nerve root as close as possible to the surface of the brainstem such that the brainstem received a maximum of 16 Gy at the 20% isodose line (Fig. 1) . Our decision to utilize beam blocking in select cases was based on 2 factors: 1) a desire to keep the pyramidal tract dose in the ventral brainstem to ≤ 16 Gy based on our petroclival and sphenoclival skull base tumor morbidity/GKS experience, and 2) a desire to treat cranial nerve V as close as possible to the root entry zone as the likely origin of the TN syndrome pathology. In all patients a state of conscious sedation was induced, and a local anesthetic was applied. After 1 night of inhospital observation, all patients were discharged home without activity restrictions. Stereotactic target imaging was performed using contrast-enhanced, short repetition time, 512 × 256 matrix, volumetric studies with 2 excitations. Secondary slicing was 1 mm in thickness in the axial plane with coronal and sagittal reconstructions. Watersoluble, nonionic, contrast-enhanced CT cisternography was used for targeting given the presence of pacemakers in 3 patients. 60 
Follow-Up Assessment Protocol
Each patient cohort was prospectively followed up on an outcomes database for up to 8.5 years, through September 2007. Patients who underwent MVD were examined and interviewed at hospital discharge and 4-6 weeks, 3-6 months, and 12 months after surgery. Patients who underwent GKS were examined and interviewed at hospital discharge and 2, 4, 6, and 12 months posttreatment. Clinic interviews and neurological examinations through December 2003 and telephone follow-up interviews thereafter through September 2007 were independently performed by a neuroscience clinical nurse specifically trained in both the interviewing and examination tasks. Patients self-rated their own degree of postoperative pain relief on a 10-point visual analog scale, with 0 being completely pain free and 10 being their preoperative level and frequency of pain. The absent or continuing need for medicine for epilepsy or pain was noted.
After the conclusion of patient accrual during January and February 2004 (0.3-4.9 years after surgery), a patient satisfaction survey with 2 questions was administered: 1) "Would you elect to undergo the same procedure again if you found yourself in similar circumstances?" and 2) "Would you recommend the same procedure to family or friends if they found themselves in similar circumstances?" This survey was repeated during August and September 2007 (3.9-8.5 years after surgery).
Statistical Analysis
Clinical outcome assessment was limited to patients with a minimum of 6 months of clinical follow-up. Differences in clinical characteristics between patient groups were compared using an analysis of variance of the means.
The durability of pain relief over time was plotted using the Kaplan-Meier life-table method and was analyzed using log-rank testing. Pain outcome status was known at the time of death for all patients who died during the follow-up, and for these patients the time of death after surgery became their censor point for life-table analysis. Given an alpha error of 5% and an anticipated success rate of 80% for MVD, this study, with its 36-44 patients per arm, had an 80% chance of detecting a 30% reduction in the outcome end point (that is, a pain-free outcome) using one-tailed analysis and 70% power using two-tailed analysis.
Results
Only 15 of 80 patients exhibited minor (< 20% of the syndrome) atypical TN features. Nine had a mild background dull, constant, or burning pain component, and this type of pain usually occurred in patients with a very long history of TN. Four patients had no initial response to AED treatment, 1 had mild associated deep ear pain, and 1 had episodic V1-associated dull headache. Subtle abnormalities on a trigeminal sensory examination were present in 20 patients (25%) including 27.8% of those who had undergone MVD and 22.7% of those treated with GKS. Sensory changes were far more common in patients who had had TN for a longer period of time.
Both patient cohorts were comparable in terms of the female/male ratio, right/left ratio (side of TN), and race (Table 1) ; however, they differed in terms of age (median 54 years for MVD versus 74 years for GKS), duration of TN symptoms (median 2.58 years for MVD versus 7.5 years for GKS), and incidence of concomitant medical problems. Each of these differences was statistically significant (p < 0.05).
During microsurgical exploration, nerve root compression by both arteries and veins was noted in 33 cases (91.7%), arteries alone in 2 cases (5.6%), and veins alone in 1 case (2.8%). A listing of the actual offending vessels encountered is presented in Table 2 . The most common artery involved in the compression was the SCA.
Clinical follow-up was performed in 100% of patients for a mean duration 3.4 ± 2.14 years (range 0.17-8.5 years). Twenty-three patients (29%) died during the follow-up, although their pain statuses were known at the time of death. No patient died as a result of the surgical intervention itself or any potential complication stemming from the TN surgery. Two patients who had undergone GKS died 2 and 4 months after surgery because of cancer and myocardial infarction, respectively, and were excluded from outcome analysis. There was a statistically insignificant trend toward a longer clinical follow-up in the MVD cohort due to a differentially high death rate during the follow-up period in the older GKS cohort (Table 3) .
Pain Relief Results
We did not identify a difference in pain relief outcome based on sex following either MVD or GKS.
All patients who had undergone MVD were initially pain free and thus required no TN medication after the intervention (Table 4 ). All patients but 1 were immediately pain free on emerging from anesthesia; 1 patient required 1 week for the TN symptoms to completely dissipate. By the last follow-up, 80.6% remained pain free while off all TN medication. There were 7 recurrences including in the 1 patient whose TN symptoms took 1 week to resolve and whose nerve compression solely by veins was noted at surgery. Recurrences in patients who had undergone MVD developed between 3 and 36 months after surgery. One patient has undergone another MVD and 3 have undergone GKS; 3 patients remained > 50% improved and at the last follow-up did not wish to undergo further therapy. Results of an actuarial life-table analysis describing clinical response are shown in Fig. 3 . Initial, 2-, and 5-year actuarial rates of a pain-free outcome were 100, 88, and 80% for MVD, respectively.
In the GKS group, 34 patients (77.3%) achieved a painfree result with no TN medication a median of 4 weeks after surgery (mean 7.4 ± 10.04 weeks, range 1 week-6 months; Table 4 ). By the last follow-up, 46.6% of patients remained pain free without medication. There were 14 recurrences between 3 months and 4.42 years after an initially pain-free outcome. In 3 cases of recurrence the patients underwent a second GKS, and in 1 case the patient underwent a trigeminal nerve section elsewhere. The remaining patients who did not die during the follow-up period continue to be managed pharmacologically with incomplete pain relief. The actuarial life-table analysis describing clinical response is shown in Fig. 3 . Initial, 2-, and 5-year actuarial rates of a pain-free outcome were 78, 50, and 33% for GKS, respectively.
Although its rates of complete pain relief were relatively lower than those for MVD, GKS was very successful in decreasing pain in patients with TN and/or reducing their AED dosing needs. The initial, 2-, and 5-year actuarial rates of > 75% pain relief were 95, 72, and 62%, respectively. Initial, 2-, and 5-year actuarial rates for > 50% pain relief were 100, 88, and 80%, respectively.
Using a pain-free-without-medication status as the objective end point, MVD performed significantly better than GKS both initially and out to 5 years (p = 0.0002, hazard ratio 0.2486, 95% confidence interval 0.1192-0.5234; Fig. 2 ). The relative risk of losing a pain-free status by 5 years after treatment was 3.35 for GKS compared with MVD. Using the looser definition of > 75% pain improvement with or without medications for GKS versus a pain-free end point for MVD, there remains a strong statistical trend in favor of MVD (p = 0.0892). It is only with a very liberal definition of success (that is, ≥ 50% pain relief with or without medications) that the results of GKS equal the pain-free status results for MVD (Fig. 3) .
Patient Satisfaction
All patients completed a patient satisfaction survey in 2004 (0.5-5 years after treatment), and 70% of those still alive in 2007 completed the same survey (3.9-8.5 years after treatment; Fig. 4 ). Among those who underwent MVD, 35 (97.2%) of 36 patients initially responded that they would elect to undergo the same procedure again if they found themselves in similar circumstances, and 1 patient (2.8%) responded with a "maybe"; 100% responded that they would recommend the same procedure to family or friends in similar circumstances. Among those who underwent GKS, 100% of patients initially responded in the affirmative to both survey questions. By 2007 (3.9-8.5 years after surgery), 100% of the responding patients in the MVD cohort answered in the affirmative to both questions. In the GKS cohort, however, only 75% of responding patients indicated that they would elect to undergo the same procedure again or would recommend the procedure to family or friends. The uniform reason given for dissatisfaction was loss of pain control leading to a negative impact on the quality of life. || The reproducible and mappable presence of � 10% subjective hypesthesia and/or hypalgesia on examination was considered significant and thus was noted. A less than 10% difference between sides was discounted as potentially due to testing technique variation. ** Minor atypical syndrome features included < 20% of the syndrome comprising a constant background component (9 cases), failure to initially respond to AED treatment (4 cases), a minor associated episodic deep ear pain component (1 case), and an occasional associated dull headache component (1 case).
Procedural Complications
There was no death or major morbidity (brainstem or cerebellar stroke, cerebellar contusion or hematoma, obstructive hydrocephalus, bacterial meningitis, and so forth) in the MVD cohort. Minor general complications were limited to 1 case of cerebrospinal fluid leaking from the wound, which was resolved with lumbar drainage. Nontrigeminal cranial nerve complications included hearing loss and diplopia in 1 patient each. There were no cases of facial weakness. Permanent mild paresthesias or numbness occurred in 2 patients (5.6%). There were no cases of permanent severe facial numbness or anesthesia dolorosa.
There was no death or major morbidity in the GKS group. One patient experienced a transient headache and a second transient attack of nausea the evening after GKS, which subsequently resolved. Cranial nerve complications were restricted to the trigeminal nerve. The mean onset of trigeminal symptoms was 3.8 ± 2.8 months after GKS (range 1 day-9 months). Three patients (6.8%) experienced permanent new mild paresthesias or numbness. One patient (2.3%) had more severe permanent sensory numbness. There was no case of trigeminal motor weakness or anesthesia dolorosa.
Discussion
The initial treatment for patients with TN remains medical. Although phenytoin and baclofen have been used with some success, carbamazepine remains the best-tested AED for TN and the gold standard of treatment. 15, 28, 33, 46, 58 Even with carbamazepine, however, 25% of patients will have inadequate initial pain relief, 6% will be intolerant of the medication due to side effects and adverse reactions, and another 13% will experience late resistance as many as 16 years after treatment, for an overall failure rate of 44%. 58 New AEDs are coming out all the time, and many are being tried in patients with TN. The newest agent with the most promise at present is oxcarbazepine. A ketoanalog of carbamazepine, it appears to be associated with less adverse reactions than carbamazepine (especially cutaneous reactions), with an apparently equivalent analgesic effect in the short term. 17, 33 An adequate long-term assessment of the durability of oxcarbazepine response has yet to be performed; however, some preliminary data have suggested that delayed resistance or recurrence remains a problem. 65 Other AEDs and other drugs often tried in patients with TN, including pregabalin, gabapentin, lamotrigine, tizanidine, topiramate, sodium valproate, and clonazepam, although potentially promising and useful, have yet to be tested in randomized clinical trial for patients with TN. 63, 64 Results of MVD For the 96-99% of patients with typical TN refrac- * After surgery all patients demonstrated a change from their preoperative condition. Abbreviations: med = medication; PF = pain free; ± = requiring or not requiring.
tory to medical therapy, who do not have a parenchymal trigeminal brainstem lesion (MS plaque or lacunar infarction) or an extrinsic mass lesion (tumor, cyst, aneurysm, arteriovenous malformation, and so forth) as the likely cause, MVD remains the surgical treatment of choice. It is the only surgical procedure specifically targeting the likely cause of the syndrome and is designed to preserve normal trigeminal function. Dandy 18 was the first to note the correlation between TN and trigeminal nerve root vascular compression. Gardner 20 was the first to attempt vascular decompression as a treatment for TN. However, it was Jannetta 23 who applied the microscope to the problem and championed and popularized the procedure over the last 41 years. 2, 3, 35, 40 Compressive vascular pathology will be identified under the microscope in > 95% of cases (100% in our series). Reports of higher rates of negative explorations 4, 12, 59 more likely represent perceived rather than real discrepancies, depending on whether one counts contact alone, veins, and/or small artery branches along with obvious "grooving" from major named arteries as significant. Multiple vessels were involved in the compression in 91.7% of our cases compared with 55.7% in a recent update by Barker et al., 3 reflecting our emphasis on identifying all potential vascular pathology, even if it is venous or small in caliper.
Since 1967, many neurosurgeons have published their results confirming the safety and efficacy of MVD for TN. A select list of larger series with longer-term followups is presented in Table 5 . As seen in this table, the longterm chance of being completely pain free while off all medications ranges between 58 and 85% (average 73.6%) with a 10-year actuarial rate of 70%. 3 Our 80.6% rate of pain-free patients without any medication compares quite favorably with rates in the best studies published to date. Whether this rate reflects our aggressive approach in addressing even small-caliper arterial branches and veins at surgery or whether it represents a statistical artifact of the smaller size of our series remains to be seen. It is also true that excluding patients with prior surgical therapies as well as those with MS will positively influence results.
Burchiel and colleagues 12 have published the only long-term follow-up study to suggest a linear recurrence rate following MVD. Most studies, including those by Barker et al., 3 Kondo, 30 Bederson and Wilson, 4 Broggi et al., 9 and Mendoza and Illingworth, 44 confirm a recurrence rate that is maximal but decreasing for the first 1-4 years after MVD and then plateaus to a rate of < 1-2%/ year by year 5 postdecompression. This leveling out and Fig. 2 . Kaplan-Meier life-table plots for maintaining pain-free status while off medication for both MVD and GKS. Initial, 2-, and 5-year actuarial pain-free rates were 100, 88, and 80% for MVD and 78, 50, and 33% for GKS, respectively. The difference in effectiveness between the 2 procedures was highly significant at p = 0.0002. Fig. 3 . Kaplan-Meier plots constructed using the looser definition of > 75% pain improvement with or without medications, demonstrating initial and 5-year actuarial success rates for GKS of 95 and 62%, respectively (A). There remained a strong statistical trend in favor of MVD (p = 0.0892). It is only with a very liberal definition of success (that is, ≥ 50% pain relief with or without medications) that GKS results equal MVD pain-free status results (B). PF = pain free.
long-term maintenance of a pain-free status over time on life-table analysis curves, along with an absent correlation between inadvertent postoperative facial numbness and a postoperative pain-free status, 2 strongly suggest that MVD is effective through relieving the cause of the syndrome rather than through an occult or subtle form of nerve root damage.
Results of GKS
Unlike MVD, palliative destructive procedures are not used to cure the syndrome by addressing its likely cause. Rather, the goal is to ameliorate symptoms through controlled damage to the trigeminal ganglion or nerve root. In essence, one trades symptom relief for the risk of trigeminal deficits from purposely inflicted subtotal nerve damage. One can damage the nerve root or ganglion by heating (RFL), 10, 27, 48, 57, 59 chemical injury (PRGR), 21, 25, 47, 61 or physically crushing the ganglion against the bone of the skull (PBC). 11, 32 Gamma Knife surgery simply represents the newest available form of rhizotomy. [6] [7] [8] 31, 41, 45, 49, 50, 52, 53, 62 With GKS the nerve root is damaged using a single extremely high dose of radiation applied to a very restricted area within the nerve root. As a result of their very nature, all palliative destructive procedures will likely share certain features. One feature is at least some risk of trigeminal numbness, dysesthesia, and/or weakness as well as potential complications arising from these deficits. Another is an approximately linear annual risk of recurrence, as visible on life-table analysis curves of the durability of pain relief, presumably due to the persistence of the underlying cause of the TN despite the palliative treatment of symptoms.
The results of GKS for TN targeting the trigeminal nerve root are presented in Table 6 . In comparison with the results of MVD studies outlined in Table 5 , it is immediately obvious that, although the chance of symptomatic improvement with GKS is attractively high (average 73.5%, range 48-95.2%), the chance of a complete painfree status without medication is much lower than with MVD (average 44%, range 24-66.7%). Our results in the present study of 45.5% of patients who were pain free without medications and 86.4% with ≥ 50% improvement in symptoms either with or without pain medications at a median follow-up of 2.9 years compare quite favorably with results achieved in larger series. Our actuarial rate of 50% of patients who were pain free 2 years after GKS, although slightly lower, is in keeping with the 58% painfree rate reported in systematic reviews of GKS results in which assessments were limited to series with life-table analyses. 37, 38 Recurrence rates after GKS have not been fully defined as yet given the relatively short follow-up periods of the studies published thus far (Table 6 ). However, there is no reason to believe that they will be significantly different from those with any other palliative destructive procedure in the sense that they will likely continue to occur at a relatively constant rate over time. Indeed, whereas an initial multiinstitutional study with a mean follow-up of 1.5 years has demonstrated a very low recurrence rate of 6.4%, 31 longer mean follow-ups of 1.7-2.2 years have yielded recurrence rates of 13.6-22.7%. 41, 50, 62 Moreover, as follow-up ranges have increased from a maximum of 4-4.1 years 50, 62 to a maximum of 6.5 years, 41 the mean and median onset of recurrence has increased from 5-8 months to 15.4 months, suggesting that recurrences continue to be experienced throughout the follow-up period. 
Comparative Results: MVD Versus GKS
Currently, there are 2 other studies in the literature in which the authors compare the results of MVD versus GKS performed by the same surgeon.
7, 49 Pollock 49 retrospectively reviewed his experience over a 5-year period with 77 patients < 70 years old, 49 who underwent MVD and 28 who were treated with GKS. With a mean followup of 2.15 years, respective actuarial rates of a pain-free status at 1 and 3 years posttreatment were 75 and 72% for MVD and 59 and 59% for GKS (p = 0.01). Brisman 7 performed a prospective cohort study of MVD versus GKS in a series of 85 patients, 24 treated with MVD and 61 with GKS. With a very short clinical follow-up, he reported respective 12-and 18-month pain-free rates of 68 and 68% for MVD and 58 and 24% for GKS. These results did not reach statistical significance (p = 0.089), and there was an unusually low success rate with MVD (68% pain free vs an average pain-free rate of 73.6% in Table 5 ) as well as an unusually low GKS treatment dose (75 Gy) and resultant pain-free success rate (24% vs an average of 44% in Table 6 ).
The current study represents the largest prospective cohort comparative analysis with the longest clinical follow-up published to date. The results for achieving pain-free status are highly significant (p = 0.0002), and the relative risk of losing a pain-free status by 5 years after treatment was 3.35 for GKS compared with that for MVD. Using evidence-based medicine criteria, 34 this study represents Class II evidence of the superiority of MVD over GKS in patients with typical TN.
In interpreting and comparing results of treatment procedures for TN, keeping careful track of the end point definitions remains imperative. The most objectively verifiable and desirable end point from a purist point of view is becoming completely pain free while off all TN medication. Note, however, that many patients may be thoroughly satisfied with a completely pain-free status on small doses of medication that do not cause any side effects. Lower degrees of pain relief are much more difficult to objectively assess and may not be as significant for the patient as they appear to be for the surgeon. Thresholds for a "good" result of ≥ 50% pain relief with or without the need for medications would appear to be extremely generous from a patient's viewpoint. 6, 31, 41, 46, 50, 62 Indeed, several patients in our study who had undergone GKS initially achieved a pain-free status while off all medication but later had a minor recurrence after which they became 80-90% pain free while on medication. Although this result would have been considered a "good" response in most GKS reports, these patients actually opted to undergo a second GKS procedure and were able to regain a pain-free status while off all medication.
Results of our patient satisfaction survey reflect this disconnect between physician-reported good results (≥ 50% or > 75% improvement in baseline pain) versus patient-perceived adequacy of results. Whereas 86.5% of the patients who had undergone GKS maintained ≥ 50% improvement in the level of pain through the last followup, only 75% were satisfied with this result to the extent that they would elect to undergo the same procedure again in similar circumstances or would recommend the same procedure to family or friends in similar circumstances.
Interpretation of Bias
Clearly this study is not a randomized clinical trial, and thus the significant differences between the patient cohorts must be carefully considered and analyzed when interpreting the comparative results. The patients in the GKS cohort were significantly older, had more significant medical comorbidities, and had suffered from TN for an average of 3 times longer than their counterparts in the MVD arm. One could argue that younger and healthier patients would do better regardless of the therapy chosen, and thus the results in this study are biased against the GKS cohort. Although this hypothesis remains feasible, it is also possible that GKS lesioning will be more effective in an older and more infirm patient as youth and health tend to favor an improved ability to repair a radiationinduced injury. Given that our GKS results compare favorably with those summarized in Table 6 , this issue is not likely to lead to a predictable bias vector. On the other hand, the duration of TN syndrome has been statistically significantly associated with a worse outcome following MVD. Barker and colleagues 3 have shown that patients with TN > 8 years have significantly worse outcomes after MVD, whereas Burchiel (unpublished data, 2007) has recently presented data suggesting that this statistical cut point for an improved outcome is actually as early as 3 years (that is, patients with TN for > 3 years have significantly worse outcomes after MVD). These associations suggest that, among patients who undergo GKS, those with a median duration of 7.5 years of TN symptoms before treatment might be expected to fare worse than those treated early in the course of their syndrome.
The use of beam-blocking patterns in > 50% of the patients who underwent GKS to limit the brainstem dose to < 16 Gy might be considered as a bias toward worse results following GKS if the dose to the brainstem trigeminal nucleus and tracts is important to success, as has been suggested by Brisman and Mooij. 8 On the other hand, beam blocking to protect the brainstem has been shown to lead to higher integral and mean doses to the trigeminal nerve compared with the doses in unblocked treatments, 43 which could lead to an accentuated therapeutic response. Overdoing the volume of nerve receiving a mean GKS dose certainly can increase complications without improving clinical outcome, as has been seen in a clinical trial of 1-versus 2-isocenter GKS treatment for TN. 19 Thus, it is difficult to infer what effect beam blocking had in our patient cohort. We did not see an increased rate of trigeminal complications, and the comparative results outlined in Table 6 would suggest that the effects are likely negligible.
Patient Satisfaction
Our patient satisfaction survey was a very simple and longitudinal measure of actual patient responses over a significant follow-up period; however, the instrument was not formally validated from an evidence-based medicine perspective. It was not assessed for reliability (that is, reproducibility or test-retest reliability), internal consistency, or validity (that is, comparison against a gold standard). As a result, the absolute values of the findings at any given time are not likely to be as reliable as the trends noticed over time. On the other hand, the changing trends in the responses to the same questions from the same patients over time do provide important data and insight for practitioners caring for those with TN.
Attractiveness and Popularity of GKS
If one carefully considers the varying definitions used to define "good" and "excellent" results in reports on palliative destructive procedures, there really does not seem to be any appreciable difference in the degree of success achievable by utilizing RFL, 10, 27, 48, 57, 59 PRGR, 21, 25, 47, 61 PBC, 11, 32 or GKS. 6, 7, 31, 41, 45, 49, 50, 52, 53, 62 The rapid and enthusiastic preference for GKS as the currently most popular palliative destructive procedure appears to be predominantly related to 1) a lower risk of numbness, unpleasant dysesthesia, or exposure keratitis; 2) a lower risk of motor trigeminal weakness; 3) the elimination of an invasive percutaneous needle; 4) the elimination of the need for pulse anesthesia during foramen ovale needle transit † Initially, 76% were pain free while off all medication; however, 34% of the 88.2% with � 50% pain relief had experienced a recurrence by the follow-up. Assuming an equal distribution between those who were pain free off all medication and those with partial improvement, the calculated percent of patients who were pain free while off all medications at the latest follow-up would be 54%.
§ No distinction was made between those who were pain free off medication and those who were pain free but requiring medication.
and actual lesioning; 5) the elimination of the reflex autonomic effects (bradycardia, tachycardia, hypotension, hypertension, and/or arrhythmias) often experienced during lesioning, which can be dangerous in elderly patients with cardiac conditions; 6) the elimination of the rare risks of meningitis, subarachnoid hemorrhage, or carotid artery-cavernous sinus fistula, occasionally seen with percutaneous procedures; and 7) the relative novelty and high technology aspects of GKS compared with other palliative destructive procedures. In the senior author's (M.E.L.) practice, GKS replaced PRGR in 1999 as the first palliative destructive procedure in a multimodality treatment algorithm for TN. The main drawback of GKS for TN from most patients' perspectives is the latency of the therapeutic effect. In our experience, the median time to pain relief is 4 weeks (mean 7.4 ± 10.04 weeks, range 1 week-6 months), which is typical of results reported by other centers. 6, 7, 31, 41, 45, 49, 50, 52, 53, 62 The main implication for a balanced multimodality TN treatment approach is that there remains a place for percutaneous palliative destructive procedures for patients who cannot, or prefer not, to undergo MVD and are clinically in extremis from pain. In our algorithm this role is filled by PRGR, with reversion to RFL if a technically satisfactory contrast cisternogram cannot be obtained. Fortunately, the majority of patients receive enough partial control from AEDs to allow time for the GKS lesion to mature and have a full effect. In our series, only 1 patient presented in extremis. She had been transferred from another hospital requiring intravenous hydration due to an inability to drink and required intravenous narcotics via a patient-controlled anesthesia pump. She was successfully treated with urgent MVD. In our practice it has now been > 9 years since we needed to perform a percutaneous palliative destructive procedure in a patient with TN.
Other GKS drawbacks to consider include the cost of treatment, which is greater than that for outpatient percutaneous destructive procedures, a possible risk of focal radiation injury to an artery compressing the trigeminal nerve root, and a probably very small risk of radiation-induced neoplasia. Maher and Pollock 42 and Pollock et al. 50 have reported on 5 patients who, after failed GKS, underwent microsurgical exploration for MVD during which was noted an isolated focal area of atherosclerosis in the segment of the SCA in contact with the trigeminal nerve root, presumably within the high dose field of the GKS treatment. Whether the area of atherosclerosis was present all along or was caused by recent GKS will remain unknown. Certainly, no patient to date has had symptoms related to potential vascular radiation injury. Loeffler 36 recently reviewed the theoretical concerns regarding stereotactic radiosurgery potentially leading to malignancy. The latency of radiation-induced malignancy is generally accepted to be ~ 7-10 years. Benign tumors show a measurably greater increased risk of latent development after single-dose exposure compared with malignant tumors. 54 Given that the multiinstitutional gamma unit study for TN began accruing patients in 1992, we are now 9 years into the period in which potential cases would start to be detected. To date, none related to the treatment of TN have been reported. On the other hand, these theoretical risks must be weighed against the small risk of death from general anesthesia during MVD added to the procedural risk of death, which in combination is estimated to be ~ 0.4%, as well as an ~ 2% risk of deafness. 64 
Problems With Current MR Imaging Tendencies
One of the biggest problems in patients with TN is that there seems to be a tacit acceptance of a flawed philosophy regarding the MR imaging workup and subsequent patient referral. The default paradigm appears to be that a patient with TN undergoes MR imaging by his or her internist or neurologist, and a radiologist interprets the results. If the report comes back with normal findings, too often vascular compression is dismissed as the cause of the TN, and the patient is instead referred to a radiosurgeon for initial treatment with minimally invasive GKS. The problem is multifaceted. First, many radiologists are not familiar with the implications of vascular contact in TN. As a result, many neuroimages considered to be positive by neurosurgeons experienced in TN are reported as nondiagnostic on official MR imaging reports by radiologists. Thus, patients who should be referred for vascular compression are not. Second, referring physicians who are not comfortable reading the images themselves and who simply refer patients based on the radiologist's report will erroneously assume the absence of vascular compression. Third, even experienced neuroradiologists or TN neurosurgeons may see only 1 vessel contacting the trigeminal nerve. During surgery, however, multiple vessel compressions have been noted in 91.7% of cases. Thus, even if a suspicious vessel is noted on MR imaging, this vessel is not likely to be the only one involved.
Even if preoperative MR imaging is successful in identifying 1 or more of the offending vessels, it rarely identifies the full extent of vascular involvement, and a negative imaging study does not mean that there is no offending vessel. As a result, we use preoperative MR imaging solely to rule out MS, trigeminal system lacunar infarction, or cerebellopontine angle mass lesions, all rare causes of TN. We also use it to assess for the presence of a Chiari malformation or compression from a dolichoectatic vertebrobasilar system, because these conditions carry slightly greater morbidity risks for the patient and are best dealt with by utilizing technical adjustments that are optimized based on prior knowledge of their presence. 35 The reality is that MR imaging-regardless of the protocol used (even volumetric contrast-enhanced T1-weighted and volumetric fine secondary slice T2-weighted protocols) and despite its utility in ruling out MS plaque, lacunar infarction, or a cerebellopontine angle mass lesion-does not have sufficient positive or negative predictive value to be recommended as a screening procedure to guide referral for the treatment of TN. If a patient has typical TN, we have found the compressing vessel in 100% of cases regardless of the preoperative MR imaging interpretation. If a patient has typical TN in the absence of MS, lacunar infarction, or a cerebellopontine angle mass, they can be safely presumed to have vascular compression and should be referred accordingly.
Adverse Consequences of Waiting
The seductive paradigm for advocating GKS over MVD suggests that a patient with TN should try minimally invasive procedures first and then progress to more invasive procedures only if radiosurgery fails. The argument often suggests that nothing is lost by performing GKS first given that more invasive procedures (for example, MVD) can always be done if GKS fails. This argument is seductive but has significant implications for the patient. First, it must be remembered that time is a very important factor in the success of MVD for TN. Barker and colleagues' 3 observation that the results of MVD significantly diminish after 8 years of suffering with TN have been confirmed and augmented by Burchiel's results (unpublished data, 2007) suggesting that the statistically significant cut point for a worsened outcome may be as soon as 3 years. Second, major MVD studies have clearly shown that a history of a palliative destructive procedure significantly worsens the outcome of subsequent MVD. 3 It would seem that a structural lesion in the trigeminal system, whether derived from naturally occurring pathology (such as MS plaque or lacunar infarction) or an iatrogenic trigeminal lesion from a palliative destructive therapeutic intervention, predisposes a patient to a worse outcome regardless of the procedure subsequently attempted. It must be remembered that a patient will never be younger, will never have a better risk for general anesthesia, and will never have a greater chance for a positive therapeutic result than at the present time.
Volume Learning Curve
Microvascular decompression is not a routine procedure with equivalent results expected from every boardcertified neurological surgeon. It is very clear that the best results are obtained from surgery performed by a surgeon mentored and trained by a master surgeon with extensive experience in MVD, who has developed a practice that includes an initial volume of patients sufficient to carry that surgeon over his or her own learning curve and an annual volume of cases sufficient to maintain skills and results of the highest possible level. 26 
Need for Both Procedures
An assessment of the results of this prospective cohort study should not lead one to conclude that MVD is always desirable over GKS. The truth is that both procedures are needed for the optimal care of a full spectrum of patients with TN. Whereas MVD should be considered superior and the first line therapy in young healthy patients with typical TN, GKS is currently the preferred choice in elderly patients and those with significant medical problems. Improving pain control and lowering the dose of cognitively and functionally debilitating medicines in the elderly and infirm patient pool is a very laudable end point, even when complete relief of pain is not a realistic goal.
Conclusions
In this prospective cohort trial, MVD was significantly superior to GKS in achieving and maintaining a pain-free status in patients with TN and provided similar early and superior longer-term rates of patient satisfaction compared with GKS. Given the literature-supported concerns that potentially worse outcomes follow MVD if the treatment is further delayed beyond the point at which a patient is no longer responding to medical therapy, as well as the concerns regarding worse MVD outcomes in a patient with a history of a destructive procedure, MVD should be the preferred first-line surgical therapy in young and healthy patients with TN. Significant training, initial and ongoing clinical experience, and careful outcome tracking are important to optimize the results of both procedures but may be even more important for MVD than GKS. Although less effective than MVD, GKS continues to play an important palliative role in patients who are older, have significant medical problems, or refuse the recommended intervention of MVD. Both surgical procedures remain important in a comprehensive, coordinated, and multidisciplinary therapeutic approach to patients with TN.
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